News
4th December 2025
Merakris Therapeutics Announces Completion of Type C Meeting with FDA – Alignment on MTX-001 Biologic Drug Development Pathway
30th September 2025
Merakris Therapeutics Secures FDA Agreement for Type C Meeting to Advance MTX-001 Development Pathway
4th September 2025
Merakris Therapeutics Enrolls 30th Subject in Expanded Access Program of MTX-001; Highlights Clinical Progress at SAWC Fall 2025
19th August 2025